Top

Published in:

01-01-2015 | Original Article

TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts

Authors: Jamie L. Croucher, Radhika Iyer, Nanxin Li, Valentina Molteni, Jon Loren, W. Perry Gordon, Tove Tuntland, Bo Liu, Garrett M. Brodeur

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2015

Abstract

Purpose

Neuroblastoma (NB) is one of the most common and deadly pediatric solid tumors. NB is characterized by clinical heterogeneity, from spontaneous regression to relentless progression despite intensive multimodality therapy. There is compelling evidence that members of the tropomyosin receptor kinase (Trk) family play important roles in these disparate clinical behaviors. Indeed, TrkB and its ligand, brain-derived neurotrophic factor (BDNF), are expressed in 50–60 % of high-risk NBs. The BDNF/TrkB autocrine pathway enhances survival, invasion, metastasis, angiogenesis and drug resistance.

Methods

We tested a novel pan-Trk inhibitor, GNF-4256 (Genomics Institute of the Novartis Research Foundation), in vitro and in vivo in a nu/nu athymic xenograft mouse model to determine its efficacy in inhibiting the growth of TrkB-expressing human NB cells (SY5Y-TrkB). Additionally, we assessed the ability of GNF-4256 to enhance NB cell growth inhibition in vitro and in vivo, when combined with conventional chemotherapeutic agents, irinotecan and temozolomide (Irino–TMZ).

Results

GNF-4256 inhibits TrkB phosphorylation and the in vitro growth of TrkB-expressing NBs in a dose-dependent manner, with an IC₅₀ around 7 and 50 nM, respectively. Furthermore, GNF-4256 inhibits the growth of NB xenografts as a single agent (p < 0.0001 for mice treated at 40 or 100 mg/kg BID, compared to controls), and it significantly enhances the antitumor efficacy of irinotecan plus temozolomide (Irino–TMZ, p < 0.0071 compared to Irino–TMZ alone).

Conclusions

Our data suggest that GNF-4256 is a potent and specific Trk inhibitor capable of significantly slowing SY5Y-TrkB growth, both in vitro and in vivo. More importantly, the addition of GNF-4256 significantly enhanced the antitumor efficacy of Irino–TMZ, as measured by in vitro and in vivo growth inhibition and increased event-free survival in a mouse xenograft model, without additional toxicity. These data strongly suggest that inhibition of TrkB with GNF-4256 can enhance the efficacy of current chemotherapeutic treatment for recurrent/refractory high-risk NBs with minimal or no additional toxicity.

Available only for authorised users

Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3(3):203–216PubMedCrossRef

Brodeur GM, Iyer R, Croucher JL, Zhuang T, Higashi M, Kolla V (2014) Therapeutic targets for neuroblastomas. Expert Opin Ther Targets 18(3):277–292PubMedCentralPubMedCrossRef

Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369(9579):2106–2120PubMedCrossRef

Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR et al (2009) Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res 15(10):3244–3250PubMedCentralPubMedCrossRef

Thiele CJ, Li Z, McKee AE (2009) On Trk—the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res 15(19):5962–5967PubMedCentralPubMedCrossRef

Nakagawara A (2001) Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 169(2):107–114PubMedCrossRef

Brodeur GM, Nakagawara A, Yamashiro DJ, Ikegaki N, Liu XG, Azar CG et al (1997) Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol 31(1–2):49–55PubMedCrossRef

Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H (1993) Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 53(9):2044–2050PubMed

Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM (1992) Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 52(5):1364–1368PubMed

10.

Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM (1993) Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328(12):847–854PubMedCrossRef

11.

Nakagawara A, Brodeur GM (1997) Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study. Eur J Cancer 33(12):2050–2053PubMedCrossRef

12.

Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC (1993) Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 85(5):377–384PubMedCrossRef

13.

Acheson A, Conover JC, Fandl JP, DeChiara TM, Russell M, Thadani A et al (1995) A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature 374(6521):450–453 see commentsPubMedCrossRef

14.

Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P et al (2002) Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 62(22):6462–6466PubMed

15.

Jaboin J, Hong A, Kim CJ, Thiele CJ (2003) Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma. Cancer Lett 193(1):109–114PubMedCrossRef

16.

Jaboin J, Kim CJ, Kaplan DR, Thiele CJ (2002) Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res 62(22):6756–6763PubMed

17.

Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ (1995) Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 55(8):1798–1806PubMed

18.

Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM (1994) Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14(1):759–767PubMedCentralPubMed

19.

Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, Thiele CJ (2006) Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Res 66(8):4249–4255PubMedCrossRef

20.

Evans AE, Kisselbach KD, Liu X, Eggert A, Ikegaki N, Camoratto AM et al (2001) Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB. Med Pediatr Oncol 36(1):181–184PubMedCrossRef

21.

Evans AE, Kisselbach KD, Yamashiro DJ, Ikegaki N, Camoratto AM, Dionne CA et al (1999) Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res 5(11):3594–3602PubMed

22.

Iyer R, Evans AE, Qi X, Ho R, Minturn JE, Zhao H et al (2010) Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin Cancer Res 16(5):1478–1485PubMedCentralPubMedCrossRef

23.

Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S et al (2011) Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol 68(4):1057–1065PubMedCentralPubMedCrossRef

24.

Iyer R, Varela CR, Minturn JE, Ho R, Simpson AM, Light JE et al (2012) AZ64 Inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts. Cancer Chemother Pharmacol (in press)

25.

Thress K, Macintyre T, Wang H, Whitston D, Liu ZY, Hoffmann E et al (2009) Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther 8(7):1818–1827PubMedCrossRef

26.

Zage PE, Graham TC, Zeng L, Fang W, Pien C, Thress K et al (2011) The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. Cancer 117(6):1321–1391PubMedCrossRef

27.

Blackwell LJ, Birkos S, Hallam R, Van De Carr G, Arroway J, Suto CM et al (2009) High-throughput screening of the cyclic AMP-dependent protein kinase (PKA) using the caliper microfluidic platform. Methods Mol Biol 565:225–237PubMedCrossRef

28.

Thompson J, Zamboni WC, Cheshire PJ, Richmond L, Luo X, Houghton JA et al (1997) Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs 8(4):313–322PubMedCrossRef

29.

Stewart CF, Zamboni WC, Crom WR, Houghton PJ (1997) Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother Pharmacol 40(3):259–265PubMedCrossRef

30.

Greco A, Mariani C, Miranda C, Pagliardini S, Pierotti MA (1993) Characterization of the NTRK1 genomic region involved in chromosomal rearrangements generating TRK oncogenes. Genomics 18(2):397–400PubMedCrossRef

31.

Greco A, Miranda C, Pagliardini S, Fusetti L, Bongarzone I, Pierotti MA (1997) Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes Cancer 19(2):112–123PubMedCrossRef

32.

Greco A, Roccato E, Pierotti MA (2004) TRK oncogenes in papillary thyroid carcinoma. Cancer Treat Res 122:207–219PubMedCrossRef

33.

Pierotti MA, Bongarzone I, Borrello MG, Mariani C, Miranda C, Sozzi G et al (1995) Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas. J Endocrinol Invest 18(2):130–133PubMedCrossRef

34.

Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D et al (2013) Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 19(11):1469–1472PubMedCrossRef

35.

Davidson B, Reich R, Lazarovici P, Ann Florenes V, Nielsen S, Nesland JM (2004) Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 83(2):119–128PubMedCrossRef

36.

Descamps S, Lebourhis X, Delehedde M, Boilly B, Hondermarck H (1998) Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells. J Biol Chem 273(27):16659–16662PubMedCrossRef

37.

Descamps S, Pawlowski V, Revillion F, Hornez L, Hebbar M, Boilly B et al (2001) Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res 61(11):4337–4340PubMed

38.

Dolle L, Adriaenssens E, El Yazidi-Belkoura I, Le Bourhis X, Nurcombe V, Hondermarck H (2004) Nerve growth factor receptors and signaling in breast cancer. Curr Cancer Drug Targets 4(6):463–470PubMedCrossRef

39.

Dolle L, El Yazidi-Belkoura I, Adriaenssens E, Nurcombe V, Hondermarck H (2003) Nerve growth factor overexpression and autocrine loop in breast cancer cells. Oncogene 22(36):5592–5601PubMedCrossRef

40.

Jin W, Kim GM, Kim MS, Lim MH, Yun C, Jeong J et al (2010) TrkC plays an essential role in breast tumor growth and metastasis. Carcinogenesis 31(11):1939–1947PubMedCrossRef

41.

Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R et al (2009) TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 28(18):1960–1970PubMedCrossRef

42.

George DJ, Suzuki H, Bova GS, Isaacs JT (1998) Mutational analysis of the TrkA gene in prostate cancer. Prostate 36(3):172–180PubMedCrossRef

43.

MacGrogan D, Saint-Andre JP, Dicou E (1992) Expression of nerve growth factor and nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines. J Neurochem 59(4):1381–1391PubMedCrossRef

44.

Pflug BR, Dionne C, Kaplan DR, Lynch J, Djakiew D (1995) Expression of a Trk high affinity nerve growth factor receptor in the human prostate. Endocrinology 136(1):262–268PubMed

45.

Walch ET, Marchetti D (1999) Role of neurotrophins and neurotrophins receptors in the in vitro invasion and heparanase production of human prostate cancer cells. Clin Exp Metastasis 17(4):307–314PubMedCrossRef

46.

Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT (2000) Rational basis for Trk inhibition therapy for prostate cancer. Prostate 45(2):140–148PubMedCrossRef

47.

Miknyoczki SJ, Wan W, Chang H, Dobrzanski P, Ruggeri BA, Dionne CA et al (2002) The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. Clin Cancer Res 8(6):1924–1931PubMed

48.

Miknyoczki SJ, Chang H, Klein-Szanto A, Dionne CA, Ruggeri BA (1999) The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin Cancer Res 5(8):2205–2212PubMed

49.

Miknyoczki SJ, Dionne CA, Klein-Szanto AJ, Ruggeri BA (1999) The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Ann N Y Acad Sci 880:252–262PubMedCrossRef

50.

Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA, Ruggeri BA (1999) Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. Int J Cancer 81(3):417–427PubMedCrossRef

51.

Sakamoto Y, Kitajima Y, Edakuni G, Sasatomi E, Mori M, Kitahara K et al (2001) Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma. Oncol Rep 8(3):477–484PubMed

52.

Euhus DM, Timmons CF, Tomlinson GE (2002) ETV6-NTRK3—Trk-ing the primary event in human secretory breast cancer. Cancer Cell 2(5):347–348PubMedCrossRef

53.

Makretsov N, He M, Hayes M, Chia S, Horsman DE, Sorensen PH et al (2004) A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosom Cancer 40(2):152–157PubMedCrossRef

54.

Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA et al (2002) Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2(5):367–376PubMedCrossRef

55.

Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH (1998) A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 18(2):184–187PubMedCrossRef

56.

Liu Q, Schwaller J, Kutok J, Cain D, Aster JC, Williams IR et al (2000) Signal transduction and transforming properties of the TEL–TRKC fusions associated with t(12, 15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J 19(8):1827–1838PubMedCentralPubMedCrossRef

57.

Rubin BP, Chen CJ, Morgan TW, Xiao S, Grier HE, Kozakewich HP et al (1998) Congenital mesoblastic nephroma t(12, 15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 153(5):1451–1458PubMedCentralPubMedCrossRef

58.

Chou TT, Trojanowski JQ, Lee VM (2000) A novel apoptotic pathway induced by nerve growth factor-mediated TrkA activation in medulloblastoma. J Biol Chem 275(1):565–570PubMedCrossRef

59.

Grotzer MA, Janss AJ, Fung K, Biegel JA, Sutton LN, Rorke LB et al (2000) TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 18(5):1027–1035PubMed

60.

Kim JY, Sutton ME, Lu DJ, Cho TA, Goumnerova LC, Goritchenko L et al (1999) Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 59(3):711–719PubMed

61.

Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL (1994) Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 91(26):12867–12871PubMedCentralPubMedCrossRef

62.

Ng YK, Wong EY, Lau CP, Chan JP, Wong SC, Chan AS et al (2012) K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr virus (EBV)—associated nasopharyngeal carcinoma cells. Invest New Drugs 30(1):48–58PubMedCrossRef

63.

McGregor LM, McCune BK, Graff JR, McDowell PR, Romans KE, Yancopoulos GD et al (1999) Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc Natl Acad Sci USA 96(8):4540–4545PubMedCentralPubMedCrossRef

64.

Eggert A, Grotzer MA, Ikegaki N, Zhao H, Cnaan A, Brodeur GM et al (2001) Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms’ tumor. J Clin Oncol 19(3):689–696PubMed

65.

Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M (1989) Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol 9(1):24–33PubMedCentralPubMed

66.

Mitra G, Martin-Zanca D, Barbacid M (1987) Identification and biochemical characterization of p70TRK, product of the human TRK oncogene. Proc Natl Acad Sci U S A 84(19):6707–6711PubMedCentralPubMedCrossRef

67.

Yu Y, Zhang S, Wang X, Yang Z, Ou G (2010) Overexpression of TrkB promotes the progression of colon cancer. Apmis 118(3):188–195PubMedCrossRef

68.

Okugawa Y, Tanaka K, Inoue Y, Kawamura M, Kawamoto A, Hiro J et al (2013) Brain-derived neurotrophic factor/tropomyosin-related kinase B pathway in gastric cancer. Br J Cancer 108(1):121–130PubMedCentralPubMedCrossRef

69.

Guo D, Hou X, Zhang H, Sun W, Zhu L, Liang J et al (2011) More expressions of BDNF and TrkB in multiple hepatocellular carcinoma and anti-BDNF or K252a induced apoptosis, suppressed invasion of HepG2 and HCCLM3 cells. J Exp Clin Cancer Res 30:97PubMedCentralPubMedCrossRef

70.

Jin W, Lee JJ, Kim MS, Son BH, Cho YK, Kim HP (2011) DNA methylation-dependent regulation of TrkA, TrkB, and TrkC genes in human hepatocellular carcinoma. Biochem Biophys Res Commun 406(1):89–95PubMedCrossRef

71.

Harada T, Yatabe Y, Takeshita M, Koga T, Yano T, Wang Y et al (2011) Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res 17(9):2638–2645PubMedCentralPubMedCrossRef

72.

Doebele R, Vaishnavi A, Capelletti M, Le A, Kako S, Butaney M et al (2013) NTRK1 gene fusions as a novel oncogene target in lung cancer. American Society of Clinical Oncology Annual Meeting 2013. ASCO University, Chicago, IL, p. suppl: abstr 8023

73.

Yu X, Liu L, Cai B, He Y, Wan X (2008) Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Sci 99(3):543–552PubMedCrossRef

74.

Desmet CJ, Peeper DS (2006) The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? Cell Mol Life Sci 63(7–8):755–759PubMedCrossRef

Title: TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts
Authors: Jamie L. Croucher
Radhika Iyer
Nanxin Li
Valentina Molteni
Jon Loren
W. Perry Gordon
Tove Tuntland
Bo Liu
Garrett M. Brodeur
Publication date: 01-01-2015
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2627-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death

Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors

Atrial natriuretic peptide protects against cisplatin-induced acute kidney injury

Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer